121 related articles for article (PubMed ID: 37497887)
1. The prognostic value of P53 index in predicting the recurrence of early low-risk endometrial cancer.
Çakır İ; Gülseren V; Aköz G; Şahin Z; Sever B; Çakır ZE; Sancı M; Kuru O; Özdemir İA; Güngördük K
J Obstet Gynaecol Res; 2023 Oct; 49(10):2487-2493. PubMed ID: 37497887
[TBL] [Abstract][Full Text] [Related]
2. The Potential Value of Ki-67 in Prognostic Classification in Early Low-Risk Endometrial Cancer.
Jia M; Pi J; Zou J; Feng M; Chen H; Lin C; Yang S; Xiao X
Cancer Control; 2023; 30():10732748231206929. PubMed ID: 37924202
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor.
Jiang P; Jia M; Hu J; Huang Z; Deng Y; Lai L; Ding S; Hu Z
Onco Targets Ther; 2020; 13():10841-10850. PubMed ID: 33149602
[TBL] [Abstract][Full Text] [Related]
4. The optimal cut-off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer.
Jia M; Jiang P; Hu J; Huang Z; Deng Y; Hu Z
Int J Gynaecol Obstet; 2021 May; 153(2):344-350. PubMed ID: 33237570
[TBL] [Abstract][Full Text] [Related]
5. The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer.
Jia M; Jiang P; Huang Z; Hu J; Deng Y; Hu Z
J Surg Oncol; 2020 Dec; 122(8):1808-1814. PubMed ID: 32920817
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Ki-67 Index in Patients With Endometrial Stromal Sarcoma.
Meng Y; Quan Q; Zhang F; Liu Y; Ren S; Mu X
Front Med (Lausanne); 2021; 8():823505. PubMed ID: 35145981
[TBL] [Abstract][Full Text] [Related]
7. Preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio as a prognostic factor in non-endometrioid endometrial cancer.
Song H; Jeong MJ; Cha J; Lee JS; Yoo JG; Song MJ; Kim JH; Lee SJ; Lee HN; Yoon JH; Park DC; Kim SI
Int J Med Sci; 2021; 18(16):3712-3717. PubMed ID: 34790044
[No Abstract] [Full Text] [Related]
8. Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer.
Li N; Jiang P; Huang Y; Tu Y; Kong W; Jiang S; Zhang J; Wu Y; Zhang X; Xie Q; Yuan R
Clin Med Insights Oncol; 2022; 16():11795549221103200. PubMed ID: 35721388
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67.
Jiang P; Yuan R
Cancer Manag Res; 2021; 13():6319-6328. PubMed ID: 34413681
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer.
Ahn JH; Lee SJ; Yoon JH; Park DC; Kim SI
Int J Med Sci; 2022; 19(14):1989-1994. PubMed ID: 36483600
[No Abstract] [Full Text] [Related]
11. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
12. Why do some patients with stage 1A and 1B endometrial endometrioid carcinoma experience recurrence? A retrospective study in search of prognostic factors.
Ocak B; Sahin AB; Oz Atalay F; Ozsen M; Dakiki B; Ture S; Sali S; Tanriverdi O; Bayrak M; Ozan H; Demiroz Abakay C; Deligonul A; Cubukcu E; Evrensel T
Ginekol Pol; 2021 Jun; ():. PubMed ID: 34105738
[TBL] [Abstract][Full Text] [Related]
13. Predicting Recurrence in Endometrial Cancer Based on a Combination of Classical Parameters and Immunohistochemical Markers.
Jiang P; Huang J; Deng Y; Hu J; Huang Z; Jia M; Long J; Hu Z
Cancer Manag Res; 2020; 12():7395-7403. PubMed ID: 32922070
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia.
Li L; Xiao Z; Wang Y; He Y; Wang Z; Shen D; Wang J
Arch Gynecol Obstet; 2023 Jun; 307(6):2025-2031. PubMed ID: 35098335
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic nutritional index for the prognosis of Chinese patients with high/extremely high-risk prostate cancer after radical prostatectomy.
Yang F; Pan M; Nie J; Xiao F; Zhang Y
World J Clin Cases; 2022 Sep; 10(25):8863-8871. PubMed ID: 36157668
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor.
Ohara M; Matsuura K; Akimoto E; Noma M; Doi M; Nishizaka T; Kagawa N; Itamoto T
Mol Clin Oncol; 2016 Apr; 4(4):648-654. PubMed ID: 27073684
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
20. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
